• Explore /
  • Poster
  • / Autologous genetically engineered NY-ESO-1<sup>c259</sup>T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Abstract Poster

Authors

null

Crystal Mackall

National Cancer Institute at the National Institutes of Health, Bethesda, MD

Crystal Mackall , Sandra P. D'Angelo , Stephan A. Grupp , Kunle Odunsi , Mihaela C. Cristea , Gerald P. Linette , Harriet M. Kluger , Gabor Kari , Lini Pandite , Tom Holdich , Elliot Norry , Gwendolyn Binder-Scholl , Rafael G. Amado

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Cellular Immunotherapy

Clinical Trial Registration Number

NCT01352286, NCT01892293, NCT01343043, NCT01567891, NCT01350401, NCT02588612

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS3101)

DOI

10.1200/JCO.2016.34.15_suppl.TPS3101

Abstract #

TPS3101

Poster Bd #

420a

Abstract Disclosures

Similar Posters

First Author: Kunle Odunsi

First Author: Apostolia Maria Tsimberidou

First Author: Hussein Abdul-Hassan Tawbi

First Author: Apostolia Maria Tsimberidou